NEXTGEN LIQUICORE PRIME PANEL BY NGS, PERIPHERAL BLOOD

image not found

NABL Cap Accredited     
The NextGen LiquiCore Prime Panel by NGS is an advanced liquid biopsy test that analyzes circulating tumor DNA (ctDNA) in the blood to detect genetic mutations linked to various cancers. It helps identify actionable targets for personalized treatment, especially for patients undergoing targeted or immunotherapy. This minimally invasive test is useful for monitoring disease progression, treatment response, and recurrence. It is an effective alternative when tissue biopsy is not feasible or poses risk

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 65,000.00

Sample Type: PERIPHERAL BLOOD

Fasting Not Required


Notes: N8284

Frequently Asked Questions (FAQ's):

What does this test evaluate?
It detects cancer-related genetic mutations present in circulating tumor DNA to support diagnosis and therapy decisions.

Who is recommended to take this test?
Cancer patients, individuals on targeted therapy, or those unable to undergo tissue biopsy.

Is fasting needed for the test?
No, fasting is not required.

How is this test helpful in cancer treatment?
It aids in selecting personalized therapies and tracking how well treatments are working.

When are the results available?
Reports are generally available within 10–14 working days

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab